Physician profile
Andreina Rojas
NPI 1245542208
$19,795.54
in general payments reported to CMS, 2019-2025
53 companies · $3,729 in 2025
The $3,729 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $1,055 · 2021: $2,749 · 2022: $3,225 · 2023: $3,729 · 2024: $3,721 · 2025: $3,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,179.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $2,401.18 | 2021-2025 | Omnipod |
| Novo Nordisk INC | $2,142.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $2,059.50 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,122.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,070.73 | 2019-2023 | Farxiga |
| Amgen INC. | $873.26 | 2019-2025 | Tepezza, Evenity, Prolia |
| Tandem Diabetes Care, INC. | $760.49 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $701.78 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mannkind Corporation | $603.17 | 2019-2025 | Afrezza |
| Amneal Pharmaceuticals LLC | $587.27 | 2019-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $581.51 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.16 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $560.49 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Radius Health, INC. | $557.21 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $497.20 | 2021-2025 | Korlym |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreina Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.